AG真人官方

STOCK TITAN
  1. Home
  2. News
  3. SSKN
  4. STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
earnings
Rhea-AI Summary
STRATA Skin Sciences (NASDAQ: SSKN) reported Q1 2025 financial results with revenue of $6.8 million, up 1% year-over-year. The company's gross margin improved significantly to 53.5%, up 790 basis points from 45.6% in Q1 2024. Global recurring XTRAC庐 revenue was $4.5 million, with international growth of 27% offsetting a 4% domestic decline. Operating expenses decreased by 5% to $5.7 million, and Adjusted EBITDA improved by $732,000 to negative $547,000. The company's direct-to-consumer strategy showed strong results, with Psoriasis and Acne patient growth of 32% and 128% respectively. International revenue grew 8% in Q1, now representing 36% of total revenue. The company reported a net loss of $2.4 million, or negative $0.58 per share, compared to a loss of $3.4 million in Q1 2024.
STRATA Skin Sciences (NASDAQ: SSKN) ha riportato i risultati finanziari del primo trimestre 2025 con un fatturato di 6,8 milioni di dollari, in crescita dell'1% rispetto all'anno precedente. Il margine lordo 猫 migliorato significativamente, raggiungendo il 53,5%, con un aumento di 790 punti base rispetto al 45,6% del primo trimestre 2024. I ricavi ricorrenti globali di XTRAC庐 sono stati di 4,5 milioni di dollari, con una crescita internazionale del 27% che ha compensato un calo domestico del 4%. Le spese operative sono diminuite del 5%, attestandosi a 5,7 milioni di dollari, e l'EBITDA rettificato 猫 migliorato di 732.000 dollari, raggiungendo un valore negativo di 547.000 dollari. La strategia diretta al consumatore ha mostrato risultati solidi, con una crescita dei pazienti con psoriasi e acne rispettivamente del 32% e del 128%. I ricavi internazionali sono cresciuti dell'8% nel primo trimestre, rappresentando ora il 36% del totale. L'azienda ha riportato una perdita netta di 2,4 milioni di dollari, o 0,58 dollari negativi per azione, rispetto a una perdita di 3,4 milioni nel primo trimestre 2024.
STRATA Skin Sciences (NASDAQ: SSKN) inform贸 los resultados financieros del primer trimestre de 2025 con ingresos de 6,8 millones de d贸lares, un aumento del 1% interanual. El margen bruto mejor贸 significativamente hasta el 53,5%, aumentando 790 puntos b谩sicos desde el 45,6% en el primer trimestre de 2024. Los ingresos recurrentes globales de XTRAC庐 fueron de 4,5 millones de d贸lares, con un crecimiento internacional del 27% que compens贸 una ca铆da dom茅stica del 4%. Los gastos operativos disminuyeron un 5% hasta 5,7 millones de d贸lares, y el EBITDA ajustado mejor贸 en 732.000 d贸lares, alcanzando un valor negativo de 547.000 d贸lares. La estrategia directa al consumidor mostr贸 resultados s贸lidos, con un crecimiento de pacientes con psoriasis y acn茅 del 32% y 128%, respectivamente. Los ingresos internacionales crecieron un 8% en el primer trimestre, representando ahora el 36% del total. La empresa report贸 una p茅rdida neta de 2,4 millones de d贸lares, o 0,58 d贸lares negativos por acci贸n, en comparaci贸n con una p茅rdida de 3,4 millones en el primer trimestre de 2024.
STRATA Skin Sciences (NASDAQ: SSKN)電� 2025雲� 1攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃橂┌ 毵れ稖 680毵� 雼煬毳� 旮半頃� 鞝勲厔 霃欔赴 雽�牍� 1% 歃濌皜頄堨姷雼堧嫟. 須岇偓鞚� 齑濎澊鞚惦鞚� 53.5%搿� 韥矊 臧滌劆霅橃柎 2024雲� 1攵勱赴鞚� 45.6% 雽�牍� 790 氩犾澊鞁滌姢 韽澑韸� 靸侅姽頄堨姷雼堧嫟. 旮�搿滊矊 XTRAC庐 氚橂车 毵れ稖鞚� 450毵� 雼煬鞓�鞙茧┌, 甑牅 毵れ稖鞚� 27% 靹膘灔頃� 甑偞 毵れ稖 4% 臧愳唽毳� 靸侅噭頄堨姷雼堧嫟. 鞓侅梾牍勳毄鞚� 5% 臧愳唽頃� 570毵� 雼煬鞓�瓿�, 臁办爼 EBITDA電� 73毵� 2觳� 雼煬 臧滌劆霅橃柎 -54毵� 7觳� 雼煬毳� 旮半頄堨姷雼堧嫟. 歆侅爲 靻岆箘鞛� 雽�靸� 鞝勲灥鞚� 臧曤牓頃� 靹标臣毳� 氤挫榾鞙茧┌, 瓯挫劆 氚� 鞐摐毽� 頇橃瀽 靾橁皜 臧侁皝 32%, 128% 歃濌皜頄堨姷雼堧嫟. 甑牅 毵れ稖鞚� 1攵勱赴鞐� 8% 靹膘灔頃� 鞝勳泊 毵れ稖鞚� 36%毳� 彀頃橁矊 霅橃棃鞀惦媹雼�. 須岇偓電� 靾滌啇鞁� 240毵� 雼煬, 欤茧嫻 -0.58雼煬毳� 氤搓碃頄堨溂氅�, 鞚措姅 2024雲� 1攵勱赴鞚� 340毵� 雼煬 靻愳嫟鞐� 牍勴暣 臧滌劆霅� 靾橃箻鞛呺媹雼�.
STRATA Skin Sciences (NASDAQ : SSKN) a publi茅 ses r茅sultats financiers du premier trimestre 2025 avec un chiffre d'affaires de 6,8 millions de dollars, en hausse de 1 % sur un an. La marge brute s'est nettement am茅lior茅e pour atteindre 53,5 %, soit une augmentation de 790 points de base par rapport 脿 45,6 % au premier trimestre 2024. Les revenus r茅currents mondiaux de XTRAC庐 se sont 茅lev茅s 脿 4,5 millions de dollars, la croissance internationale de 27 % compensant une baisse de 4 % sur le march茅 domestique. Les d茅penses d'exploitation ont diminu茅 de 5 % pour atteindre 5,7 millions de dollars, et l'EBITDA ajust茅 s'est am茅lior茅 de 732 000 dollars pour atteindre un montant n茅gatif de 547 000 dollars. La strat茅gie directe au consommateur a donn茅 de bons r茅sultats, avec une croissance des patients atteints de psoriasis et d'acn茅 de 32 % et 128 % respectivement. Les revenus internationaux ont progress茅 de 8 % au premier trimestre, repr茅sentant d茅sormais 36 % du chiffre d'affaires total. La soci茅t茅 a enregistr茅 une perte nette de 2,4 millions de dollars, soit une perte de 0,58 dollar par action, contre une perte de 3,4 millions au premier trimestre 2024.
STRATA Skin Sciences (NASDAQ: SSKN) meldete die Finanzergebnisse f眉r das erste Quartal 2025 mit einem Umsatz von 6,8 Millionen US-Dollar, was einem Anstieg von 1 % im Jahresvergleich entspricht. Die Bruttomarge verbesserte sich deutlich auf 53,5%, ein Anstieg um 790 Basispunkte gegen眉ber 45,6 % im ersten Quartal 2024. Die globalen wiederkehrenden XTRAC庐-Ums盲tze betrugen 4,5 Millionen US-Dollar, wobei ein internationales Wachstum von 27 % einen inl盲ndischen R眉ckgang von 4 % ausglich. Die Betriebskosten sanken um 5 % auf 5,7 Millionen US-Dollar, und das bereinigte EBITDA verbesserte sich um 732.000 US-Dollar auf minus 547.000 US-Dollar. Die Direktvertriebsstrategie zeigte starke Ergebnisse, mit einem Wachstum der Psoriasis- und Akne-Patienten von 32 % bzw. 128 %. Die internationalen Ums盲tze wuchsen im ersten Quartal um 8 % und machen nun 36 % des Gesamtumsatzes aus. Das Unternehmen meldete einen Nettoverlust von 2,4 Millionen US-Dollar bzw. minus 0,58 US-Dollar je Aktie, verglichen mit einem Verlust von 3,4 Millionen im ersten Quartal 2024.
Positive
  • Gross margin improved significantly by 790 basis points to 53.5%
  • Operating expenses reduced by 5% year-over-year
  • Strong international revenue growth of 27% in XTRAC and 8% overall
  • Impressive DTC strategy results with 32% growth in Psoriasis patients and 128% in Acne patients
  • Adjusted EBITDA improved by $732,000 compared to prior year
Negative
  • Minimal revenue growth of only 1% year-over-year
  • 4% decline in domestic XTRAC revenue
  • Continued net loss of $2.4 million
  • Negative operating cash flow of $550,000
  • Negative Adjusted EBITDA of $547,000

Insights

STRATA shows modest revenue growth but significant operational improvements with expanding margins and reduced losses, though remains unprofitable.

STRATA Skin Sciences posted marginal revenue growth of 1% in Q1 2025, reaching $6.8 million. While top-line growth appears anemic, the company has made substantial operational improvements that deserve attention.

The most impressive metric is the gross margin expansion of 790 basis points year-over-year, reaching 53.5% compared to 45.6% in Q1 2024. This significant margin improvement demonstrates enhanced operational efficiency and potentially better pricing power.

Disciplined cost management is evident with operating expenses declining 5% to $5.7 million, with notable reductions across all categories 鈥� engineering & product development (down 60%), selling & marketing (down 1%), and general & administrative (down 5%).

These operational improvements have substantially narrowed STRATA's losses. Adjusted EBITDA improved by $732,000 to negative $547,000 (versus negative $1.3 million in Q1 2024), while net loss decreased to $2.4 million from $3.4 million a year earlier.

The company's XTRAC business shows a mixed performance. While domestic recurring revenue declined 4%, international growth of 27% helped offset this weakness. The average revenue per domestic XTRAC system increased 3% to $4,776, indicating better monetization of the installed base despite fewer treatments.

STRATA's international expansion is becoming increasingly important, now representing 36% of total revenue. With 8% growth in Q1 (following 41% growth in the previous quarter), this segment appears to be a key growth driver that could help stabilize the overall business.

With $7.8 million in cash and improved operating cash flow (though still negative at $550,000), the company has some financial runway, but continued progress toward profitability is essential for long-term sustainability.

HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (鈥淪TRATA鈥� or the 鈥淐ompany鈥�) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update.

First Quarter 2025 Financial Highlights

  • Revenue in the first quarter of 2025 was $6.8 million, up 1%
    • Global net recurring XTRAC庐 revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic market
    • Average net revenue per domestic XTRAC庐 system increased to $4,776 (+3% YoY) on 846
    • Total Recurring revenue increased 1% to $4.7 million in the first quarter
    • Equipment revenue for the first quarter was $2.1 million, up 1.4% from the year-ago period
  • Gross margin in the first quarter was 53.5%, up 790 basis points from 45.6% in the prior year period
  • Operating expenses in the first quarter were $5.7 million, down 5% as compared to the year-ago period
  • Operating cash flow improved by $254 thousand to negative $550 thousand
  • Adjusted EBITDA improved by $732 thousand to negative $547 thousand versus negative $1.3 million in the prior year period
  • Total cash at quarter end was $7.8 million

鈥淪TRATA made solid progress in the first quarter in executing our strategic plan,鈥� said Dr. Dolev Rafaeli, STRATA President and CEO. 鈥淎long with a modest increase in revenue, we have significantly improved our gross margins, expanding nearly 800 basis points year over year. We have also maintained disciplined cost control resulting in a decline in operating expenses and improvement in our seasonally low first quarter adjusted EBITDA.

鈥淥ur existing direct-to-consumer (DTC) strategy continues to strengthen, driving 32% and 128% more unique Psoriasis and Acne patients respectively, as compared to prior year period demonstrating both growing demand and improved marketing efficiency.

鈥淚nternationally, we鈥檙e building strong momentum. Revenue from international markets grew 8% in Q1 as compared to prior year, following 41% growth in the previous quarter. This segment now accounts for 36% of our total revenue, and we anticipate, once the global tariff uncertainty clears it will continue to grow, adding strong growth to our U.S. business stabilization and growth,鈥� concluded Dr. Rafaeli.

First Quarter 2025 Financial Results

Revenue for the first quarter of 2025 was $6.8 million, an increase of 1% versus the first quarter of 2024. Global recurring revenue of $4.7 million and equipment revenue of $2.1 million in the first quarter of 2025 were each up roughly 1% over the prior-year first quarter.

Gross profit for the first quarter of 2025 was $3.6 million, or 53.5% of revenue, as compared to $3.1 million, or 45.6% of revenue, for the first quarter of 2024.

Total operating expenses of $5.7 million in the first quarter of 2025 declined 5% versus the prior-year period, with engineering & product development down 60%, selling & marketing down 1%, and general & administrative down 5% versus their prior-year levels.

Net loss for the first quarter of 2025 was $2.4 million, or EPS of negative $0.58 per basic and diluted common share, as compared to a net loss of $3.4 million, or EPS of negative $0.96 per basic and diluted common share, in the first quarter of 2024.

Cash, cash equivalents, and restricted cash at March 31, 2025 were $7.8 million.

First Quarter 2025 Earnings Conference Call

STRATA management will host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management鈥檚 formal remarks, there will be a question-and-answer session.

To listen to the conference call, interested parties within the U.S. should dial 1-866-524-3160 (domestic) or 1-412-317-6760 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.

The conference call will also be available through a live webcast that can be accessed at

A telephonic replay of the call will be available until May 21, 2025 by dialing 1-877-344-7529 (or 1-412-317-0088 for international toll callers) and using replay access code 6753445. To access the replay using an international dial-in number, please see

A will be available approximately one hour after the live call and remain accessible until September 21, 2025.

Non-GAAP Financial Measures

STRATA has determined to supplement its consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America (鈥淯.S. GAAP鈥�), presented elsewhere within this report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP gross profit, which excludes the non-cash expense of amortization of acquired intangible assets classified as cost of revenues, and non-GAAP adjusted EBITDA, 鈥淓arnings Before Interest, Taxes, Depreciation, and Amortization.鈥�

These non-GAAP disclosures have limitations as an analytical tool, should not be viewed as a substitute for Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP, should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. STRATA considers these non-GAAP measures in addition to its results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers鈥� overall understanding of STRATA鈥檚 current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that the Company's future results will be unaffected by similar adjustments to Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, STRATA believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of the Company鈥檚 core operating results and business outlook. In addition, STRATA believes non-GAAP measures enhance the comparability of results against prior periods.

Reconciliation to the most directly comparable U.S. GAAP measure of all non-GAAP measures included in this press release is as follows:

听Three Months Ended March 31,
(in thousands)听2025听听听2024听
Net loss$(2,432)听$(3,368)
听听听听
Adjustments:听听听
Depreciation and amortization听1,220听听听1,249听
Amortization of operating lease right-of-use asset听85听听听95听
Loss on disposal of property and equipment听34听听听13听
Interest expense, net听417听听听479听
Non-GAAP EBITDA听(676)听听(1,532)
Stock-based compensation听129听听听112听
Inventory write-off听-听听听141听
Non-GAAP adjusted EBITDA$(547)听$(1,279)
听听听听

XTRAC Gross Domestic Recurring Billings

XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.

The following is a reconciliation of non-GAAP XTRAC gross domestic billings to domestic recorded revenue for the first听quarter of 2025 and 2024 (in thousands), respectively:

听Three Months Ended March 31,
(in thousands)听2025听听听2024听
Gross domestic recurring billings$4,086听听$4,578听
Co-Pay adjustments听(74)听听(80)
Other Discounts听(4)听听(30)
Deferred revenue from prior quarters听1,545听听听1,624听
Deferral of revenue to future quarters听(1,513)听听(1,901)
GAAP domestic revenue$4,041听听$4,190听
听听听听

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC庐听excimer laser, VTRAC庐听lamp systems, and the TheraClear庐X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA鈥檚 popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company鈥檚 plans, objectives, expectations and intentions and may contain words such as 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渟eeks,鈥� and 鈥渆xpects,鈥� that suggest future events or trends. These statements, the Company鈥檚 ability to launch and sell products recently acquired or to be developed in the future, the Company鈥檚 ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company鈥檚 ability to build a leading franchise in dermatology and aesthetics, are based on the Company鈥檚 current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company鈥檚 expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company鈥檚 SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at听听and听.

Investor Contact:
CORE IR
516-222-2560
听

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
听
听March 31, 2025听December 31, 2024
听(unaudited)听听
Assets听听听
Current assets:听听听
Cash and cash equivalents6,512听听7,261听
Restricted cash1,334听听1,334听
Accounts receivable, net of allowance for credit losses of $548 and $466 at March31, 2025 and December 31, 2024, respectively5,007听听5,253听
Inventories2,659听听2,246听
Prepaid expenses and other current assets364听听501听
Total current assets15,876听听16,595听
Property and equipment, net9,462听听10,061听
Operating lease right-of-use assets1,179听听1,264听
Intangible assets, net4,856听听5,348听
Goodwill2,658听听2,658听
Other assets231听听231听
Total assets34,262听听36,157听
听听听听
Liabilities and Stockholders' Equity听听听
Current liabilities:听听听
Accounts payable2,816听听2,433听
Accrued expenses and other current liabilities8,779听听8,593听
Deferred revenues2,204听听2,241听
Current portion of operating lease liabilities331听听328听
Current portion of contingent consideration1,009听听1,030听
Total current liabilities15,139听听14,625听
Long-term debt, net15,231听听15,192听
Deferred revenues and other liabilities292听听353听
Operating lease liabilities, net of current portion835听听919听
Contingent consideration, net of current portion96听听96听
Total liabilities31,593听听31,185听
Commitments and contingencies听听听
Stockholders equity:听听听
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding-听听-听
Common stock, $0.001 par value; 150,000,000 shares authorized; 4,171,161 shares issued and outstanding at both March 31, 2025 and December 31, 20244听听4听
Additional paid-in capital253,241听听253,112听
Accumulated deficit(250,576)听(248,144)
Total stockholders' equity2,669听听4,972听
Total liabilities and stockholders' equity34,262听听36,157听
听听听听


STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
听
听Three Months Ended March 31,
听听2025听听听2024听
Revenues, net$6,812听听$6,754听
Cost of revenue听3,165听听听3,674听
Gross profit听3,647听听听3,080听
Operating expenses听听听
Engineering and product development听96听听听241听
Selling and marketing听2,993听听听3,018听
General and administrative听2,573听听听2,710听
Total operating expenses听5,662听听听5,969听
Loss from operations听(2,015)听听(2,889)
Other income (expense):听听听
Interest expense听(486)听听(524)
Interest income听69听听听45听
Total other expense听(417)听听(479)
Net loss$(2,432)听$(3,368)
听听听听
Net loss per share of common stock, basic and diluted$(0.58)听$(0.96)
Weighted average shares of common stock outstanding, basic and diluted听4,171,161听听听3,506,025听
听听听听


STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(in thousands)
听
听Three Months Ended March 31,
听听2025听听听2024听
Cash flows from operating activities:听听听
Net loss$(2,432)听$(3,368)
Adjustments to reconcile net loss ot net cash provided by (used in) operating activities:听听听
Depreciation and amortization听1,220听听听1,249听
Amortization of operating lease right-of-use assets听85听听听95听
Amortization of deferred financing costs and debt discount听39听听听31听
Change in allowance for credit losses听110听听听84听
Stock-based compensation expense听129听听听112听
Loss on disposal of property and equipment听34听听听13听
Inventory write-off听-听听听141听
Changes in operating assets and liabilities:听听听
Account receivable听136听听听726听
Inventories听(377)听听(154)
Prepaid expenses and other assets听137听听听(31)
Accounts payable听362听听听261听
Accrued expenses and other liabilities听169听听听(57)
Deferred revenues听(81)听听194听
Operating lease liabilities听(81)听听(100)
Net cash provided by (used in) operating activities听(550)听听(804)
Cash flows from investing activities:听听听
Purchase of property and equipment听(199)听听(725)
Net cash used in investing activities听(199)听听(725)
Cash flows from Financing activities:听听听
Payment of contingent consideration听-听听听(18)
Net cash provided by financing activities听-听听听(18)
Net decrease in cash, cash equivalents and restricted cash听(749)听听(1,547)
Cash, cash equivalents and restricted cash at beginning of period听8,595听听听8,118听
Cash, cash equivalents and restricted cash at end of period$7,846听听$6,571听
听听听听
Supplemental disclosure of cash flow information:听听听
Cash paid during the year for interest$450听听$480听
听听听听
Supplemental schedule of non-cash operating, investing, and financing activities:听听听
Operating lease right-of-use assets obtained in exchange for operating lease$-听听$977听
Transfer of property and equipment to inventories$36听听$9听
Accrued payment of contingent consideration$21听听$6听
听听听听

FAQ

What were STRATA Skin Sciences (SSKN) key financial results for Q1 2025?

STRATA reported Q1 2025 revenue of $6.8 million (+1% YoY), gross margin of 53.5% (+790 bps), and a net loss of $2.4 million (-$0.58 per share). Operating expenses decreased 5% to $5.7 million.

How did STRATA's XTRAC business perform in Q1 2025?

Global XTRAC recurring revenue was $4.5 million, with 27% international growth offsetting a 4% domestic decline. Average revenue per domestic XTRAC system increased 3% to $4,776.

What was STRATA's (SSKN) cash position at the end of Q1 2025?

STRATA reported total cash, cash equivalents, and restricted cash of $7.8 million as of March 31, 2025.

How did STRATA's international business perform in Q1 2025?

International revenue grew 8% in Q1 2025 and now represents 36% of total revenue, with XTRAC international growth of 27% year-over-year.

What were the results of STRATA's direct-to-consumer (DTC) strategy in Q1 2025?

STRATA's DTC strategy showed strong results with 32% growth in unique Psoriasis patients and 128% growth in Acne patients compared to the prior year.
Stock SSKN logo
Strata Skin Sciences Inc

NASDAQ:SSKN

SSKN Rankings

#10046 Ranked by Market Cap
N/A Ranked by Dividends

SSKN Latest News

Aug 7, 2025
STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients
Jul 31, 2025
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update
May 19, 2025
STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases
May 8, 2025
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
May 7, 2025
STRATA Skin Sciences to Report First Quarter 2025 Financial Results on听May 14, 2025 and Provide Corporate Update

SSKN Latest SEC Filings

Aug 7, 2025
[8-K] Strata Skin Sciences, Inc. Reports Material Event

SSKN Stock Data

7.97M
2.57M
4.02%
64.11%
0.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
HORSHAM

Related Articles

Continue reading with these related stories

View All Latest News